Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cholesterol drug and a blood pressure drug be safely combined?

NCT ID NCT07784608

Knowledge-focused Sponsor: Huons Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This early-stage trial asks whether taking atorvastatin (a cholesterol-lowering drug) and telmisartan (a blood pressure drug) together changes how the body absorbs and clears each one. Healthy adult volunteers will receive each drug alone and then both together, so researchers can compare blood levels. The goal is to see if the two medicines can be co-administered without unexpected interactions, which could support future combination therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of atorvastatin (HUC2-744-A) and telmisartan (HUC2-744-B)
What this could lead to
If the two drugs don't interfere with each other, it could support combining them in a single pill, simplifying treatment for people who need both a cholesterol-lowering and a blood-pressure-lowering medicine.
What could go wrong
This is an early-stage, small study in healthy volunteers, so results may not reflect real-world patients. The drugs could interact in ways that affect safety or dosing.
Why investors are watching

Huons is running a Phase 1 trial in 28 healthy volunteers to check whether its two experimental drugs, HUC2-744-A and HUC2-744-B, interfere with each other when taken together. For a small company, this readout matters because it will show whether the drugs can be co-administered safely, which is a basic step before any later-stage testing. A clear result could validate the company's development path, while a problematic interaction would force a redesign of the dosing plan.

If it works: If the trial shows no meaningful drug-drug interaction, Huons can move the combination forward into later studies with more confidence. That positive data could strengthen the company's pipeline narrative and support its clinical development plans.

If it fails: If the trial reveals a significant interaction or safety issue, Huons may need to adjust dosing, delay the program, or abandon the combination. Phase 1 trials often fail or reveal problems, so a negative result is a real possibility for a company of this size.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults * Subjects with a body weight of 50 kg or more and a BMI within the range of 18.0 to 29.9 kg/m² Exclusion Criteria: * History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease * Presence of acute disease symptoms within 28 days prior to the first dosing * History of any disease that may affect drug absorption, distribution, metabolism, or excretion * Hypersensitivity or history of clinically significant hypersensitivity to atorvastatin, telmisartan, drugs containing ingredients of the same class, or other medications (e.g., aspirin, antibiotics, dihydropyridine derivatives)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-drug interactions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug-drug interactions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Korea University Anam Hospital

    Seoul, Seongbuk-gu, 02841, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.